Phathom Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized.
PHATHOM PHARMACEUTICALS, INC.
/s/ Steven Basta
Steven BastaChief Executive Officer
Date: February 26, 2026
Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Steven BastaSteven Basta | President, Chief Executive Officer andDirector (Principal Executive Officer) | February 26, 2026 |
| /s/ Sanjeev NarulaSanjeev Narula | Chief Financial and Business Officer (Principal Financial Officer) | February 26, 2026 |
| /s/ Michael F. ColaMichael F. Cola | Director | February 26, 2026 |
| /s/ Frank KarbeFrank Karbe | Director | February 26, 2026 |
| /s/ Heidi KunzHeidi Kunz | Director | February 26, 2026 |
| /s/ Asit ParikhAsit Parikh, M.D., Ph.D. | Director | February 26, 2026 |
| /s/ Ted SchroederTed Schroeder | Director | February 26, 2026 |
| /s/ Mark StenhouseMark Stenhouse | Director | February 26, 2026 |
| /s/ James TopperJames Topper, M.D., Ph.D. | Director | February 26, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.